OakChart

Inhibrx Biosciences Inc

INBXHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

90.59-0.02 (-0.02%)
2026-11-12 03:29 CET
Market cap
1,333.28 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-138.18 USD m
Free cash flow, TTM
-131.90 USD m
EPS diluted, TTM
-8.88
P/E
-
Compare

Price

INBX against its 20, 50 and 200-day averages
2050200beat
60.0080.00100.00120.00140.00838K1.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26INBXclose 90.5920-day 86.7450-day 96.79200-day 92.5790.5952w high

41.7% under the 52-week high of 155.29 on 22 Apr 2026. 52-week low 57.30 on 27 Mar 2026. Last 15 sessions, 50.0% high to low

Volume 0.55× normal · the line is the 50-bar volume average

Profile

INBX
52-week range, 34% of the way up
57.30155.29

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

IndexRUT
Employees110
IPOMay 29, 2024
Beta3.88
ATR, 14d6.89
Rel volume0.55
Short float30.92%
Insider own25.55%
Inst own84.37%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.33B
Enterprise Value1.38B
Income-138.18M
Sales0.00M
Book/sh-3.60
Cash/sh9.06
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees110
IPOMay 29, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C10.00
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio5.07
Current Ratio5.07
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-8.88
EPS next Y-8.94
EPS next Q-2.45
EPS this Y-5.27%
EPS next Y6.09%
EPS next 5Y15.68%
EPS past 3/5Y3.40% -
Sales past 3/5Y-15.98% -
EPS Y/Y TTM19.23%
Sales Y/Y TTM-100.00%
EPS Q/Q-26.26%
Sales Q/Q-100.00%
EarningsAug 13 AMC
EPS/Sales Surpr.-2.63% -

Ownership

Insider Own25.55%
Insider Trans1.62%
Inst Own84.37%
Inst Trans3.04%
ROA-75.44%
ROE-1773.60%
ROIC-109.53%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA204.44%
SMA50-6.41%
SMA200-2.14%
Trades-

Technical

Shs Outstand14.71M
Shs Float10.96M
Short Float30.92%
Short Ratio11.15
Short Interest3.39M
52W High155.29 -41.66%
52W Low57.30 58.10%
Volatility7.03% 8.73%
ATR (14)6.89
RSI (14)51.68
Beta3.88
Rel Volume0.55
Avg Volume304.08K
Volume165,742

Performance

Perf Week4.41%
Perf Month4.03%
Perf Quarter-6.62%
Perf Half Y-23.20%
Perf YTD14.67%
Perf Year16.38%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.50
Target Price266.67
Prev Close90.61
Price90.59
Change %-0.02%

Analyst ratings

latest 3 of 3
DateActionAnalystRating changeTargetImplied
Aug 24, 2026InitiatedHH.C. WainwrightBuy$245+170.4%
Apr 08, 2026InitiatedSStifelBuy$150+65.6%
Jul 23, 2024InitiatedJJMP SecuritiesMkt Perform

Peers

Mkt cap
TickerCompanyMkt cap
XNCRXencor Inc3.00B
ZYMEZymeworks BC Inc2.02B
IMNMImmunome Inc2.25B
MGNXMacrogenics Inc147.78M
JANXJanux Therapeutics Inc758.06M
CMPXCompass Therapeutics Inc149.51M
CTMXCytomX Therapeutics Inc464.35M
SMMTSummit Therapeutics Inc13.27B
TNGXTango Therapeutics Inc4.36B
ADCTAdc Therapeutics SA204.27M

Insider trading

latest 14 of 18
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Lappe MarkChief Executive OfficerOct 14 '26Buy84.5610,040848,977745,588Oct 14 06:58 PM
Lappe MarkChief Executive OfficerSep 25 '26Buy99.165,500545,357736,048Sep 28 05:47 PM
Lappe MarkChief Executive OfficerSep 28 '26Buy100.764,500453,426740,548Sep 28 05:47 PM
Kayyem Jon FaizDirectorSep 23 '26Buy100.005,000500,000434,360Sep 23 04:59 PM
Kayyem Jon FaizDirectorSep 16 '26Buy100.005,000500,000429,360Sep 17 05:46 PM
MANHARD KIMBERLYDirectorSep 11 '26Sale111.7850055,8888,500Sep 15 05:52 PM
MANHARD KIMBERLYDirectorSep 14 '26Sale110.2650055,1308,000Sep 15 05:52 PM
MANHARD KIMBERLYDirectorSep 15 '26Sale105.0550052,5257,500Sep 15 05:52 PM
MANHARD KIMBERLYDirectorSep 15 '26Proposed Sale105.0550052,525Sep 15 04:02 PM
MANHARD KIMBERLYDirectorSep 14 '26Proposed Sale110.2650055,130Sep 14 04:57 PM
MANHARD KIMBERLYDirectorSep 11 '26Proposed Sale111.7850055,888Sep 11 01:15 PM
MANHARD KIMBERLYDirectorSep 09 '26Sale115.8050057,8989,000Sep 10 07:06 PM
MANHARD KIMBERLYDirectorSep 08 '26Sale115.1450057,5709,500Sep 10 07:06 PM
MANHARD KIMBERLYDirectorSep 09 '26Proposed Sale115.8050057,898Sep 09 05:15 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IBBiShares Biotechnology ETFAUM: 11.36B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
FYCFirst Trust Small Cap Growth AlphaDEX FundAUM: 1.35B
DWASInvesco Dorsey Wright SmallCap Momentum ETFAUM: 391.13M

News

latest 14 of 80
  • Inhibrx Announces Participation in Upcoming Scientific Conferences (PR Newswire)
  • Inhibrx Shares Rise After Positive Phase 2 Head and Neck Cancer Data (InvestorsHub) -5.64%
  • Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study (PR Newswire)
  • Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study (PR Newswire)
  • Inhibrx Reports Second Quarter 2026 Financial Results (PR Newswire) -8.91%
  • Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million (PR Newswire)
  • Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma (PR Newswire)
  • Inhibrx Reports First Quarter 2026 Financial Results (PR Newswire) -6.47%
  • This Surging Biotech Stock Shrugs Off Positive Cancer Trial Results and Slips. What to Know. (Barrons.com) -5.04%
  • Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy (PR Newswire)
  • Inhibrx delivers differentiated cancer drug data; Fractyl starts diabetes gene therapy trial (BioPharma Dive)
  • Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC (PR Newswire) +7.89%
  • Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer (PR Newswire) +36.88%
  • Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer (PR Newswire) -6.62%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-2.340-2.280-2.3400.000.002
2026Q12026-05-14-2.150-1.675-2.1460.000.002
2025Q42026-03-19-2.110-2.080-2.1140.000.001
2025Q32025-11-14-2.280-1.720-2.2780.000.001
2025Q22025-08-13-1.850-2.760-1.8531.300.002
2025Q12025-05-14-2.800-2.835-2.8000.000.002
2024Q42025-03-17-3.090-2.885-3.3070.100.002
2024Q32024-11-14-2.840-3.380-3.0300.000.002
2024Q22024-08-13125.48-3.600128.350.100.001
2024Q12024-05-29-1.440--5.4370.00--
2023Q42024-02-28-1.730-1.037-6.4661.630.05-
2023Q32023-11-09-1.100-1.010-3.5780.120.00-
2023Q22023-08-07-1.080-1.033-3.2500.030.00-
2023Q12023-05-08-1.120-0.843-3.3790.020.10-
2022Q42023-03-06-0.950-0.788-0.270.99-
2022Q32022-11-07-0.900-0.941-0.280.63-

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-3.010-2.638-2.83512.8911.10
2021FY-2.150-2.158-2.1507.236.10
2022FY-3.620-3.363-10.0322.192.60
2023FY-5.120-4.393-16.6731.800.25
2024FY112.62111.6116.580.200.10
2025FY-9.040-9.010-9.0401.301.30
2026FY--9.517--0.00
2027FY--8.937--36.07
2028FY--5.420--120.8
2029FY--2.800--202.56
2030FY-2.670--353.6

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-213000.000.000.00
2026Q3S2026-08-142000.000.000.00
2026Q3S2026-08-132000.000.000.00
2026Q3S2026-05-152000.000.000.00
2026Q3S2026-04-062000.000.000.00
2026Q3S2026-03-201000.000.000.00
2026Q3S2026-02-011000.000.000.00
2026Q3S2025-11-181010.000.000.00
2026Q3S2025-11-141011.901.901.90
2026Q3S2025-11-111011.901.901.90
2026Q3S2025-11-101011.901.901.90
2026Q3S2025-11-091011.901.901.90
2026Q3S2025-11-081011.901.901.90
2026Q3S2025-11-071011.901.901.90

Estimate history

EPS, annual-10.032-16.673116.578-9.043-8.8764
Period2022202320242025TTM
EPS, quarterly128.352-3.03-3.307-2.8-1.853-2.278-2.114-2.146-2.339
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual2.1921.80.21.30
Period2022202320242025TTM
Sales, quarterly0.100.101.30000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual14.47614.47614.47614.57814.709
Period2022202320242025MRQ
Shares, quarterly14.47614.47614.47614.47614.47614.49814.57814.60714.709
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Total Revenue0.001.300.201.802.19
Cost of Goods Sold Incl. D&A2.212.482.291.19-
Gross Profit-2.21-1.18-2.080.61-
Selling, General and Administrative Excl. Other125.61133.84329.36219.83130.08
Research and Development100.82110.72201.86190.65109.18
Other Operating Expense0.000.000.000.000.00
Operating Income-127.81-135.03-331.45-219.22-129.12
Interest Expense15.5712.2013.4931.8418.18
Unusual Expense0.000.00-2,021.500.000.00
Net Income Before Taxes-138.18-140.051,687.57-239.72-145.22
Income Taxes0.000.000.000.000.00
Consolidated Net Income-138.18-140.061,687.57-241.36-145.23
Net Income From Continuing Operations-138.18-140.061,687.57-241.36-145.23
Net Income-138.18-140.061,687.57-241.36-145.23
EPS (Recurring)-8.82-9.0418.83-16.67-10.03
EPS (Basic, Before Extraordinaries)-8.88-9.04116.58-16.67-10.03
EPS (Diluted)-8.88-9.04116.58-16.67-10.03
EBITDA-125.61-132.54-329.16-218.03-127.89
Non-Operating Income (Expense)5.207.1711.0211.342.08
Other After Tax Adjustments0.000.000.000.000.00
Stock Option Compensation Expense10.438.8046.2319.6316.16
Price To Sales Ratio-941.131,114.64--
Gross Margin--91.00-1,042.5033.83-
Operating Margin--10,386.54-165,724.00-12,178.94-5,890.37
Net Margin--10,773.46843,786.00-13,408.94-6,625.27
Shares Outstanding14.7114.5814.4814.4814.48
Market Capitalization1,333.281,333.28222.93219.17-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.001.300.000.100.00
Cost of Goods Sold Incl. D&A0.520.540.560.580.660.680.690.76
Gross Profit-0.52-0.54-0.56-0.580.64-0.68-0.59-0.76
Selling, General and Administrative Excl. Other31.6330.3930.3633.2328.0342.2349.3446.04
Research and Development23.3824.6924.7927.9621.6836.2932.7838.23
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-32.15-30.93-30.92-33.81-27.39-42.90-49.93-46.80
Interest Expense5.693.513.193.183.142.69-0.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-36.65-33.44-32.83-35.26-28.65-43.31-47.87-43.86
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-36.65-33.44-32.83-35.26-28.65-43.31-47.87-43.86
Net Income From Continuing Operations-36.65-33.44-32.83-35.26-28.65-43.31-47.87-43.86
Net Income-36.65-33.44-32.83-35.26-28.65-43.31-47.87-43.86
EPS (Recurring)-2.34-2.15-2.11-2.28-1.85-2.80-3.31-3.03
EPS (Basic, Before Extraordinaries)-2.34-2.15-2.11-2.28-1.85-2.80-3.31-3.03
EPS (Diluted)-2.34-2.15-2.11-2.28-1.85-2.80-3.31-3.03
EBITDA-31.63-30.39-30.36-33.23-26.73-42.23-49.24-46.04
Non-Operating Income (Expense)1.200.991.271.741.882.282.062.93
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.102.652.172.512.192.452.362.96
Price To Earnings Ratio----0.120.12--
Price To Sales Ratio-805.98943.93372.36157.661,081.991,114.64130.73
Gross Margin----49.08--589.00-
Operating Margin-----2,106.85--49,928.00-
Net Margin-----2,204.15--47,865.00-
Shares Outstanding14.7114.6114.5814.5014.4814.4814.4814.48
Market Capitalization1,333.28982.031,148.95487.87206.57202.52222.93226.69

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY
Cash & Short Term Investments124.22152.60277.92273.87
Short Term Receivables0.180.420.780.26
Inventories0.000.000.000.00
Other Current Assets8.447.3816.666.37
Total Current Assets132.83160.40295.36280.49
Net Property, Plant & Equipment9.2713.549.377.22
Total Investments and Advances0.000.000.000.00
Intangible Assets0.000.000.000.00
Other Assets4.386.833.163.16
Total Assets146.48180.77307.89290.88
Short Term Debt Incl. Current Port. of LT Debt2.331.592.061.86
Accounts Payable5.949.2410.958.33
Other Current Liabilities25.5329.8943.3017.39
Total Current Liabilities33.8040.7356.3127.58
Long Term Debt104.696.45208.08205.24
Provision for Risks Charges0.000.000.000.00
Other Liabilities0.000.000.000.00
Total Liabilities138.4947.18264.39232.82
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.00
Common Equity7.99133.5843.5058.06
Total Shareholders Equity7.99133.5843.5058.06
Accumulated Minority Interest0.000.000.000.00
Total Equity7.99133.5843.5058.06
Total Liabilities & Stockholders Equity146.48180.77307.89290.88
Book Value Per Share0.559.233.014.01
Tangible Book Value Per Share0.559.233.014.01
Full-Time Employees110161--
Price to Book Ratio-25.151.251.23-
Return on Assets-85.60690.69-80.62-
Return on Equity-197.851,905.92-475.31-
Return on Invested Capital-124.301,205.09-95.94-55.16
Quick Ratio3.933.945.2510.17
Current Ratio3.933.945.2510.17

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Net Income-138.18-140.061,687.57-241.36-145.23
Depreciation2.212.482.291.191.23
Other Funds (Non Cash)16.9115.39-1,936.3231.5125.54
Funds from Operations-119.06-122.18-246.46-208.66-118.46
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital-12.82-7.6152.0515.353.16
Cash from Operating Activities-131.89-129.79-194.41-193.31-115.30
Capital Expenditures-0.01-0.03-2.60-4.59-0.69
Net Assets From Acquisitions0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.00
Purchase of Investments0.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.00
Other Uses0.000.000.000.000.00
Other Sources0.000.000.000.000.00
Cash from Investing Activities-0.01-0.03-2.60-4.59-0.69
Cash Dividends Paid0.000.000.000.000.00
Change in Capital Stock3.681.6171.68201.96129.74
Repurchase of Common Pref Stock0.000.000.000.000.00
Sale of Common Pref Stock3.681.6171.68201.96129.74
Proceedsfrom Stock Options0.000.000.00-0.35126.98
Issuance or Reduction of Debt, Net74.9999.840.000.000.00
Change in Long Term Debt74.990.000.000.000.00
Issuance of Long Term Debt74.990.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.00128.81
Other Financing Activities Uses0.000.000.000.00-0.05
Cash from Financing Activities78.67101.4571.68201.96258.55
Net Change in Cash-53.22-28.38-125.334.06142.56
Free Cash Flow-131.90-129.82-197.01-197.90-115.99
Preferred Dividends (Cash Flow)-0.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments133.34161.66124.22153.09186.57216.52
Short Term Receivables0.130.190.180.840.970.21
Inventories0.000.000.000.000.000.00
Other Current Assets8.749.508.447.506.436.65
Total Current Assets142.21171.34132.83161.42193.96223.39
Net Property, Plant & Equipment7.248.259.2710.3111.3512.45
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets4.774.384.385.746.816.80
Total Assets154.22183.97146.48177.47212.12242.64
Short Term Debt Incl. Current Port. of LT Debt2.492.412.332.252.171.97
Accounts Payable9.808.765.946.778.298.89
Other Current Liabilities15.7715.3425.5326.9628.4832.77
Total Current Liabilities28.0626.5133.8035.9838.9443.64
Long Term Debt179.13178.49104.69104.66104.62104.56
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities207.20205.00138.49140.64143.56148.20
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-52.98-21.047.9936.8368.5694.44
Total Shareholders Equity-52.98-21.047.9936.8368.5694.44
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-52.98-21.047.9936.8368.5694.44
Total Liabilities & Stockholders Equity154.22183.97146.48177.47212.12242.64
Book Value Per Share-3.60-1.440.552.544.746.52
Tangible Book Value Per Share-3.60-1.440.552.544.746.52
Full-Time Employees--110---
Price to Book Ratio-25.15122.6131.107.112.191.52
Return on Assets-75.44-61.03-85.60-77.54-69.58648.69
Return on Equity-1,773.60-354.69-197.85-144.07-113.713,250.55
Return on Invested Capital-29.05-21.24-29.14-24.92-16.55-21.76
Quick Ratio5.076.463.934.494.985.12
Current Ratio5.076.463.934.494.985.12

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-36.65-33.44-32.83-35.26-28.65-43.31
Depreciation0.520.540.560.580.660.68
Other Funds (Non Cash)4.913.873.864.273.843.42
Funds from Operations-31.22-29.04-28.41-30.40-24.15-39.22
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital1.30-8.99-1.72-3.42-5.803.32
Cash from Operating Activities-29.92-38.03-30.12-33.82-29.95-35.90
Capital Expenditures0.000.000.00-0.010.00-0.02
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.00-0.010.00-0.02
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.600.471.250.350.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.600.471.250.350.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.0074.990.000.000.0099.84
Change in Long Term Debt0.0074.990.000.000.000.00
Issuance of Long Term Debt0.0074.990.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.6075.461.250.350.0099.84
Net Change in Cash-28.3137.44-28.87-33.48-29.9563.92
Free Cash Flow-29.92-38.03-30.12-33.83-29.95-35.92

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 200.00K 2025: 1.30M
United States2024: 200.00K 2025: 1.30M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3030.92%3.4M11.0M298.89K
2026-10-1531.18%3.4M11.0M278.46K
2026-09-3031.29%3.4M11.0M307.32K
2026-09-1530.91%3.4M11.0M316.22K
2026-08-3129.93%3.3M11.0M301.68K
2026-08-1429.20%3.2M11.0M305.55K
2026-07-3130.74%3.3M10.9M379.84K
2026-07-1531.59%3.4M10.9M470.44K
2026-06-3031.71%3.4M10.9M445.68K
2026-06-1530.84%3.3M10.7M426.84K
2026-05-2929.30%3.2M10.9M405.61K
2026-05-1524.42%2.9M12.0M381.67K
2026-04-3026.69%2.7M10.2M294.91K
2026-04-1520.87%2.1M10.2M211.79K
2026-03-3120.74%2.1M10.2M199.38K
2026-03-1318.24%1.9M10.2M209.17K
2026-02-2716.97%1.7M10.2M206.72K
2026-02-1317.04%1.7M10.2M227.11K
2026-01-3017.06%1.7M10.2M256.64K
2026-01-1516.20%1.7M10.2M404.41K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call30.0056.0066.0044.007.7011.000.000.955-0.4370.013
call35.0051.0061.0087.606.7411.000.000.939-0.5330.017
call40.0046.0056.000.005.9380.000.000.929-0.5260.019
call45.0041.0050.9054.225.2061.000.000.918-0.5150.021
call50.0036.0045.9032.404.5990.000.000.919-0.4080.021
call55.0031.0040.900.004.0520.000.000.907-0.3950.023
call60.0026.0035.900.003.5520.000.000.876-0.4660.029
call65.0021.0030.900.003.0890.000.000.827-0.6210.036
call70.0017.0025.006.092.42310.000.000.854-0.3390.032
call75.0012.0021.006.002.2603.000.000.767-0.5380.043
call80.008.0017.007.162.0606.000.000.723-0.4820.047
call85.006.0014.009.252.01614.000.000.640-0.6830.053
call90.003.6011.007.001.9101852.000.568-0.5940.055
call95.001.0010.005.842.1013230.000.504-0.6480.056
call1000.455.503.251.60181.006.000.394-0.4950.054
call1050.1010.004.001.5704.000.000.316-0.4480.050
call1100.2010.001.752.09334.000.000.333-0.6100.051
call1150.0010.003.502.30237.000.000.314-0.6540.050
call1200.1010.000.802.4932180.000.299-0.6920.049
call1250.1510.001.402.67054.000.000.286-0.7260.048
call1300.1010.000.202.8341360.000.275-0.7570.047
call1350.0010.002.252.9883.000.000.266-0.7850.046
call1400.0010.0034.503.1333.000.000.259-0.8110.046
call1450.0010.000.503.27028.000.000.252-0.8340.045
call1500.009.905.003.39932.000.000.246-0.8560.044
call1550.0010.001.803.5221.000.000.241-0.8760.044
call1600.0010.0010.223.6397.000.000.236-0.8950.043
call1650.0010.001.503.7502.000.000.231-0.9130.043
call1700.0010.001.403.8572.000.000.227-0.9300.043
call1750.0010.001.303.9593.000.000.224-0.9460.042
call1800.0010.001.904.0586.000.000.220-0.9610.042
call1850.007.501.103.5775.000.000.178-0.7070.039
call1900.0010.001.904.2433.000.000.215-0.9890.041
call1950.002.201.902.9603.000.000.076-0.3380.020
call2000.001.200.672.8762790.000.075-0.3080.021
call2100.0010.001.903.1672.000.000.072-0.3480.019
call2200.0010.001.703.2941.000.000.070-0.3550.019
call2300.0010.000.303.4147.000.000.069-0.3600.019
put30.000.0010.000.005.7010.000.00-0.045-0.4340.013
put35.000.0010.000.004.9860.000.00-0.053-0.4300.015
put40.000.006.900.704.3762.000.00-0.061-0.4230.017
put45.000.0010.001.853.8432.000.00-0.071-0.4140.019
put50.000.0010.002.553.3681.000.00-0.081-0.4020.021
put55.000.0010.000.002.9370.000.00-0.093-0.3890.023
put60.000.0010.002.702.54161.000.00-0.107-0.3730.026
put65.000.0010.003.002.1721410.00-0.124-0.3540.029
put70.000.0010.001.801.82341.000.00-0.146-0.3310.032
put75.000.005.009.602.1821.000.00-0.233-0.5290.043
put80.000.005.006.501.78217.000.00-0.277-0.4730.047
put85.001.1510.003.102.33322.0050.00-0.360-0.6740.053
put90.001.7010.005.301.85228.000.00-0.432-0.5840.055
put95.005.0012.7012.801.8132670.00-0.496-0.6380.056
put1008.0015.9016.001.8004.000.00-0.606-0.4840.054
put10511.5021.0031.102.0853.000.00-0.641-0.5460.053
put11017.0025.0020.202.1317.000.00-0.667-0.5980.051
put11521.0030.0031.902.34217.000.00-0.686-0.6410.050
put12026.0034.0033.002.3286.000.00-0.701-0.6790.049
put12531.0039.0034.272.50311.000.00-0.714-0.7130.048
put13035.0044.900.002.6650.000.00-0.725-0.7430.047
put13539.9049.000.002.8170.000.00-0.734-0.7700.046
put14044.2054.0031.462.9601.000.00-0.741-0.7950.046
put14549.2059.000.003.0950.000.00-0.748-0.8180.045
put15054.1064.000.003.2230.000.00-0.754-0.8390.044
put15559.1069.000.003.3450.000.00-0.759-0.8590.044
put16064.1074.000.003.4610.000.00-0.764-0.8770.043
put16569.1079.000.003.5720.000.00-0.769-0.8950.043
put17074.1084.000.003.6780.000.00-0.773-0.9110.043
put17579.1089.000.003.7790.000.00-0.776-0.9260.042
put18084.1094.000.003.8770.000.00-0.780-0.9410.042
put18589.1099.000.003.9710.000.00-0.783-0.9550.041
put19094.101040.004.0620.000.00-0.785-0.9680.041
put19599.101090.004.1490.000.00-0.924-0.3160.020
put200104.11140.004.2340.000.00-0.925-0.3190.020
put210114.11240.004.3950.000.00-0.928-0.3250.019
put220124.11340.004.5460.000.00-0.930-0.3300.019
put230134.11440.004.6880.000.00-0.931-0.3350.019

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-28SCHEDULE 13G/ASEC
2026-10-144Statement of changes in beneficial ownership of securities2026-10-14SEC
2026-09-288-KCurrent report2026-09-28SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-25SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-23SEC
2026-09-184/A2026-06-03SEC
2026-09-184/A2026-06-03SEC
2026-09-184/A2026-06-03SEC
2026-09-184/A2026-06-03SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-16SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-14144Filing for proposed sale of securities under Rule 144.SEC
2026-09-11144Filing for proposed sale of securities under Rule 144.SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-09144Filing for proposed sale of securities under Rule 144.SEC
2026-09-088-KCurrent report2026-09-08SEC
2026-09-08144Filing for proposed sale of securities under Rule 144.SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-03SCHEDULE 13GSEC
2026-07-168-KCurrent report2026-07-15SEC
2026-06-158-KCurrent report2026-06-15SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10848.98K100
2026-095.50M7279.01K5
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
MORGAN STANLEY8.92%
PERCEPTIVE ADVISORS LLC8.85%
Sanofi7.87%
VIKING GLOBAL INVESTORS LP7.66%
HighTower Advisors, LLC6.01%
BANK OF AMERICA CORP /DE/5.73%
BlackRock, Inc.5.63%
Schonfeld Strategic Advisors LLC4.75%
STATE STREET CORP4.37%
VANGUARD CAPITAL MANAGEMENT LLC3.36%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF2.73%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.52%
SMALLCAP World Fund Inc2.41%
iShares Russell 2000 ETF1.66%
The Merger Fund1.35%
VANGUARD EXTENDED MARKET INDEX FUND0.75%
Fidelity Small Cap Index Fund0.71%
Meridian Small Cap Growth Fund0.66%
iShares Biotechnology ETF0.52%
First Trust Small Cap Growth AlphaDEX Fund0.51%

OakChart. INBX. Cached 15 minutes.